首页 | 本学科首页   官方微博 | 高级检索  
检索        

肾移植术后肝肾功能损害患者应用他克莫司切换环孢素的临床观察
引用本文:张丽华,李建新,高柏青,刘志中,刘文豹,韩培红,刘增,韩利忠.肾移植术后肝肾功能损害患者应用他克莫司切换环孢素的临床观察[J].解放军药学学报,2013(2):169-172.
作者姓名:张丽华  李建新  高柏青  刘志中  刘文豹  韩培红  刘增  韩利忠
作者单位:[1]内蒙医学院第三附属医院药剂科,内蒙古包头014010 [2]内蒙医学院第三附属医院泌尿外科,内蒙古包头014010 [3]内蒙医学院第三附属医院核医学科,内蒙古包头014010
摘    要:目的观察他克莫司切换环孢素A治疗肾移植术后肝、肾功能损害患者的安全性及临床疗效。方法将33例肾移植术后肝、肾功能异常的患者分为4组:术后直接使用他克莫司组(Ⅰ组,8例);术后1年内切换他克莫司组(Ⅱ组,9例);术后2~4年切换他克莫司组(Ⅲ组,9例);术后5年以上切换他克莫司组(Ⅳ组,7例)。观察用他克莫司替换环孢素A12、24个月后各组患者肝、肾功能的变化情况。结果肾移植术后1年内切换他克莫司的患者,切换12个月时血肌酐由切换前的(133.21±40.92)μmol·L-1降至(116.86±35.41)μmol·L-1,呈明显下降趋势,但差异无统计学意义;移植术后2~4年切换他克莫司的患者,切换24个月时,患者的血肌酐由(138.00±15.72)μmol·L-1降至(109.76±9.68)μmol·L-1,下降较显著(P〈0.05),差异有统计学意义;术后5年以上切换他克莫司患者,切换12个月时,血肌酐变化不大,差异无统计学意义。结论用他克莫司替换环孢素A治疗肾移植术后肝、肾功能损害是一种安全而有效的措施。

关 键 词:肾移植  他克莫司  环孢菌素

Clinical Study of CsA Substituted by Tacrolinus in Recipients with Hepatic and/or Renal Dysfunction After Kidney Transplantation
ZHANG Li-hua,LI Jian-xin,GAO Bai-qing,LIU Zhi-zhong,LIU Wen-bao,HAN Pei-hong,LIU Zeng,HAN Li-zhong.Clinical Study of CsA Substituted by Tacrolinus in Recipients with Hepatic and/or Renal Dysfunction After Kidney Transplantation[J].Pharmaceutical Journal of Chinese People's Liberation Army,2013(2):169-172.
Authors:ZHANG Li-hua  LI Jian-xin  GAO Bai-qing  LIU Zhi-zhong  LIU Wen-bao  HAN Pei-hong  LIU Zeng  HAN Li-zhong
Institution:Department of Pharmacy, Urology Surgery, Nuclear Medicine Department, the Third Affiliated Hospital of Inner Mongolia Medical College, Baotou 014010 ,China
Abstract:Objective To evaluate the therapeutic efficacy and safety of CsA substituted by tacrolinus (FK506) in renal allograft recipients with hepatic and/or renal dysfunction. Methods 33 cases of renal allograft re- cipients with hepatic and/or renal dysfunction were divided into four guoups : the first group consisted of recipients who used FK506 directly after kidney transplantation ( n = 8 ) ;the second group was composed of recipients who had CsA substituted by FK506 one year after kidney transplantation ( n = 9 ) ;the third group two-four years after kidney transplantation ( n = 9) and the fourth group more than five years after kidney transplantation ( n = 7). The changes of hepatic and renal function were observed for 12 or 24 monthes in all the recipients. Results Twelve months after conversion from CsA to FKS06 in recipients of the second group, the level of serum creatinine( μmol L - 1 ) decreased significantly from 133.21 ± 40.92 to 116.86 ± 35.41, but of no statistic significance. After twen- ty-four months the level of serum creatinine( μmol L-1 ) decreased significantly ( P 〈0.05 ) from 138.00 ±15.72 to 109.76 ± 9.68 in the third group. There was no significantly different in the level of serum creatinine in recipi- ents of the fourth group after twelve months. Conclusion FK506 substitution of CsA is an effective and safe approach to hepatic and/or graft dysfunction which occurs in renal allograft recipeients.
Keywords:kidney transplantation  acrolimus  cyclosporine
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号